Health Vidya

Azacitidine for injection (Azacitidine), is indicated for treatment of adult patients with the following French-American British (FAB) myelodysplastic syndrome subtypes: refractory anemia (RA) or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL). Pediatric use information is approved for Bristol-Myers Squibb’s Vidaza (azacitidine for injection). However, due to Bristol-Myers Squibb’s marketing exclusivity rights, this drug product is not labeled with that information.